Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Immune Checkpoint Inhibitors Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Key Companies in the Market - Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, AstraZeneca, Seagen, Roche

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

13 Jun, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the immune checkpoint inhibitors market are expected to change in the coming years owing to the rising cancer cases, increasing healthcare spending across the globe, and the anticipated launch of novel and emerging immune checkpoint inhibitors, and others.

LAS VEGAS, June 13, 2023 /PRNewswire/ -- DelveInsight's Immune Checkpoint Inhibitors Competitive Landscape report delivers an in-depth understanding of the immune checkpoint inhibitors and the immune checkpoint inhibitors market trends in the 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Immune Checkpoint Inhibitors Market Report

  • DelveInsight analysis shows that the immune checkpoint inhibitors market is expected to grow positively due to several underline factors during the study period (2019–2032).
  • Leading immune checkpoint inhibitors companies such as Regeneron Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim, Xencor, Inc., Taiga Biotechnologies, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Dr. Reddys Laboratories, SA, NATCO Pharma Ltd., AstraZeneca, EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., SQZ Biotechnologies, Teon Therapeutics, Inc., ALX Oncology, Astellas Pharma Inc, Seagen Inc., Hoffmann-La Roche, NextCure, Inc., MiNK Therapeutics, Genmab, BioNTech SE, STORM Therapeutics LTD, Suzhou Kintor Pharmaceutical Inc, Sanofi, Coordination Pharmaceuticals, Inc., and others are developing novel immune checkpoint inhibitors that can be available in the immune checkpoint inhibitors market in the coming years.
  • Some key immune checkpoint inhibitors include Fianlimab (REGN-3767), Cobolimab (GSK-4069889), Tiragolumab (RG-6058), Ezabenlimab (BI-754091), XmAb22841, TBX-3400, KN046, E7777, NRC-2694-A, Olaparib, M1774, Nivolumab, IMSA101, N-803 + Pembrolizumab, SQZ-AAC-HPV, TT-816, ALX148, Enfortumab vedotin, RO7247669, NC410, agenT-797, GEN1046, STC-15, GT90001 + Nivolumab, SAR408701, RiMO-301, and others.
  • Several immune checkpoint inhibitors are awaiting approval, while some immune checkpoint inhibitors are in the advanced stages of development. 

Discover which immune checkpoint inhibitors are expected to grab the major immune checkpoint inhibitors market share @ Immune Checkpoint Inhibitors Market Report

Immune Checkpoint Inhibitors Overview

Cancer immunotherapy uses the patient's own immune system to combat cancer, as opposed to conventional cancer medicines, which directly target tumor cells. Immune checkpoints are pathways that have inhibitory or stimulatory properties and help in the immune response. The cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is an inhibitory checkpoint, as are the programmed cell death receptor-1 (PD-1) and programmed cell death ligand-1 (PD-L1). The current situation presents significant obstacles to further advancement. One important problem is the scarcity of major biomarkers, which necessitates the use of diverse clinical study designs for efficacy evaluation.

New immune checkpoints with either stimulatory or inhibitory functions are developing, with important roles in controlling T cell response but also affecting other critical effectors of the innate immune response (e.g., natural killer). TIGIT, ICOS, OX-40, LAG-3, TIM-3, B7-H3, and other immune checkpoint inhibitor targets have sparked attention.

Immune Checkpoint Inhibitors Market Insights

Cancer immunotherapy is fast advancing and is now regarded as the "fifth pillar" of cancer therapy, alongside surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The most popular CI involves antibodies to inhibitory immune checkpoint molecules. The immune system is a network of cells, tissues, and organs that work together to protect the body from outside invaders such as bacteria or viruses. Lymphocytes are a type of white blood cell (WBC) that plays a critical role in bodily defense. Natural killer (NK) cells, B cells, and T cells are the three major kinds of lymphocytes.

The immune system is divided into two parts: the humoral immune response and the cell-mediated immunological response. These two sides collaborate to maintain the body free of infections. B-cells produce antibodies in the blood as part of the humoral immune response, which aids in the fight against infections in the lymph or blood and provides long-term immunity against subsequent infections.

Checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccinations, virus therapies, adoptive cell transfer, and T-cell therapy, and targeted medicines are all types of immunotherapy. Immunotherapy has become a prominent focus of anticancer therapeutic regimens with good reason: when it succeeds, patients can have long-lasting antitumor immune responses that not only destroy primary tumors but also metastasis lesions. Immune Checkpoint Inhibitors have been the most prominent kind of immunotherapy in Oncology.

Immune checkpoint inhibitors currently under research address a varied variety of different immune targets, including LAG-3, TIGIT, ICOS, OX-40, TIM-3, B7-H3, CD47-SIRP receptor, and a few others, in addition to well-established targets such as PD-1, PDL-1, and CTLA-4.

To know more about immune checkpoint inhibitors, visit @ Immune Checkpoint Inhibitors Analysis

Key Immune Checkpoint Inhibitors Drugs and Companies

  • Fianlimab (REGN-3767): Regeneron Pharmaceuticals
  • Cobolimab (GSK-4069889): GlaxoSmithKline
  • Tiragolumab (RG-6058): Roche
  • Ezabenlimab (BI-754091): Boehringer Ingelheim
  • XmAb22841: Xencor, Inc.
  • TBX-3400: Taiga Biotechnologies, Inc.
  • KN046: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
  • E7777: Dr. Reddys Laboratories, SA
  • NRC-2694-A: NATCO Pharma Ltd.
  • Olaparib: AstraZeneca
  • M1774: EMD Serono Research & Development Institute, Inc.
  • Nivolumab: Bristol-Myers Squibb
  • IMSA101: ImmuneSensor Therapeutics Inc.
  • N-803 + Pembrolizumab: ImmunityBio, Inc.
  • SQZ-AAC-HPV: SQZ Biotechnologies
  • TT-816: Teon Therapeutics, Inc.
  • ALX148: ALX Oncology
  • Enfortumab vedotin: Astellas Pharma Inc/Seagen Inc.
  • RO7247669: Hoffmann-La Roche
  • NC410: NextCure, Inc.
  • agenT-797: MiNK Therapeutics
  • GEN1046: Genmab/BioNTech SE
  • STC-15: STORM Therapeutics LTD
  • GT90001 + Nivolumab: Suzhou Kintor Pharmaceutical Inc
  • SAR408701: Sanofi
  • RiMO-301: Coordination Pharmaceuticals, Inc.

Learn more about the FDA-approved immune checkpoint inhibitors @ Approved Immune Checkpoint Inhibitors 

Immune Checkpoint Inhibitors Market Dynamics

The dynamics of the immune checkpoint inhibitors market are predicted to change in the coming years. The immune checkpoint inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the immune checkpoint inhibitors market in the 7MM.

However, several factors are impeding the growth of the immune checkpoint inhibitors market. The of immune checkpoint inhibitors market growth may be offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists. Thus, these factors mentioned above will hamper the growth of the immune checkpoint inhibitors market.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Key Immune Checkpoint Inhibitors Companies

Regeneron Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim, Xencor, Inc., Taiga Biotechnologies, Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Dr. Reddys Laboratories, SA, NATCO Pharma Ltd., AstraZeneca, EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, ImmuneSensor Therapeutics Inc., ImmunityBio, Inc., SQZ Biotechnologies, Teon Therapeutics, Inc., ALX Oncology, Astellas Pharma Inc, Seagen Inc., Hoffmann-La Roche, NextCure, Inc., MiNK Therapeutics, Genmab, BioNTech SE, STORM Therapeutics LTD, Suzhou Kintor Pharmaceutical Inc, Sanofi, Coordination Pharmaceuticals, Inc., and others

Key Immune Checkpoint Inhibitors Therapies

Fianlimab (REGN-3767), Cobolimab (GSK-4069889), Tiragolumab (RG-6058), Ezabenlimab (BI-754091), XmAb22841, TBX-3400, KN046, E7777, NRC-2694-A, Olaparib, M1774, Nivolumab, IMSA101, N-803 + Pembrolizumab, SQZ-AAC-HPV, TT-816, ALX148, Enfortumab vedotin, RO7247669, NC410, agenT-797, GEN1046, STC-15, GT90001 + Nivolumab, SAR408701, RiMO-301, and others

Scope of the Immune Checkpoint Inhibitors Market Report

  • Therapeutic Assessment: Current Marketed and Emerging Immune Checkpoint Inhibitors 
  • Immune Checkpoint Inhibitors Market Dynamics: Attribute Analysis of Emerging Immune Checkpoint Inhibitors 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Immune Checkpoint Inhibitors Market Access and Reimbursement

Discover more about immune checkpoint inhibitors in clinical development @ Immune Checkpoint Inhibitors in Clinical Trials

Table of Contents

1.

Immune Checkpoint Inhibitors Market Key Insights

2.

Immune Checkpoint Inhibitors Market Report Introduction

3.

Immune Checkpoint Inhibitors Market Overview at a Glance

4.

Immune Checkpoint Inhibitors Market Executive Summary

5.

Disease Background and Overview

6.

Immune Checkpoint Inhibitors Marketed Drugs

7.

Immune Checkpoint Inhibitors Emerging Drugs

8.

Seven Major Immune Checkpoint Inhibitors Market Analysis

9.

Immune Checkpoint Inhibitors Market Outlook

10.

Potential of Current and Emerging Therapies

11.

KOL Views

12.

Immune Checkpoint Inhibitors Market Drivers

13.

Immune Checkpoint Inhibitors Market Barriers

14.

Unmet Needs

15.

SWOT Analysis

16.

Appendix

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

Related Reports

Checkpoint Inhibitors Competitive Landscape

Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.